{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:22:39Z","timestamp":1760059359004,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C4002746","RS-2024-00335798"],"award-info":[{"award-number":["NRF-2021R1A2C4002746","RS-2024-00335798"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["NRF-2021R1A2C4002746","RS-2024-00335798"],"award-info":[{"award-number":["NRF-2021R1A2C4002746","RS-2024-00335798"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Fexofenadine hydrochloride (FEX) is widely used to treat allergic rhinitis. However, poor solubility, high cohesiveness, and risk of polymorphic transformation present significant formulation challenges. Conventional FEX tablet formulations are large and may pose swallowing difficulties for patients with dysphagia. Therefore, a miniaturized FEX tablet that maintained bioequivalence with the marketed product was developed. Methods: An organic solvent-based binder and porous carrier enhanced solubility, flowability, and process efficiency. The formulation was optimized using a design of experiments approach to assess the effects of tablet size and porous carrier incorporation on dissolution and residual solvent content. Scale-up feasibility was evaluated using Froude number-based process optimization, and stability studies were conducted under accelerated conditions (40 \u00b0C and 75% relative humidity) to ensure long-term formulation robustness. Results: The miniaturized tablet exhibited dissolution at pH 4.0 and pH 6.8 equivalent to that of the reference product, whereas a faster dissolution rate was observed at pH 1.2. No significant changes were observed in the dissolution rate, crystalline structure, or impurity levels over six months. An in vivo bioequivalence study demonstrated that the test formulation met the bioequivalence criteria, with 90% confidence intervals for the area under the curve and the Cmax falling within the regulatory acceptance range. Conclusions: A miniaturized and commercially viable fexofenadine hydrochloride tablet was developed (44% weight reduction and 50% volume reduction compared to the marketed product). The organic solvent-based binder and porous carrier system improved manufacturing efficiency, stability, and solubility, thereby ensuring compliance with regulatory standards. These findings provide valuable insights into size reduction, solubility enhancement, and large-scale production strategies for the development of future pharmaceutical formulations.<\/jats:p>","DOI":"10.3390\/pharmaceutics17060756","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T08:22:34Z","timestamp":1749457354000},"page":"756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation and Bioequivalence Evaluation of a Miniaturized Fexofenadine Hydrochloride Tablet"],"prefix":"10.3390","volume":"17","author":[{"given":"Woo-Yul","family":"Song","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea"},{"name":"Yuyu Pharma, Inc., Seoul 04598, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-9098","authenticated-orcid":false,"given":"Chang-Soo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Sang","family":"Yu","sequence":"additional","affiliation":[{"name":"Yuyu Pharma, Inc., Seoul 04598, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Jang","sequence":"additional","affiliation":[{"name":"Yuyu Pharma, Inc., Seoul 04598, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyoung-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Yuyu Pharma, Inc., Seoul 04598, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Shin","family":"Jeon","sequence":"additional","affiliation":[{"name":"Yuyu Pharma, Inc., Seoul 04598, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9897-889X","authenticated-orcid":false,"given":"Young-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8739-7253","authenticated-orcid":false,"given":"So-Jeong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-9160","authenticated-orcid":false,"given":"Ji-Hyun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jeonbuk National University, Jeonju 54896, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wonkwang University, Iksan-si 54670, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-9921","authenticated-orcid":false,"given":"Yun-Sang","family":"Park","sequence":"additional","affiliation":[{"name":"P2KBio, Cheongju 28160, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-8443","authenticated-orcid":false,"given":"Chun-Woong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"ref_1","first-page":"95","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat. Rev. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.waojou.2023.100824","article-title":"Prevalence, severity, and risk factors of allergic rhinitis among schoolchildren in Saudi Arabia: A national cross-sectional study, 2019","volume":"16","author":"Alnahas","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Husna, S.M.N., Tan, H.-T.T., Shukri, N.M., Ashari, N.S.M., and Wong, K.K. (2022). Allergic Rhinitis: A clinical and pathophysiological overview. Front. Med., 9.","DOI":"10.3389\/fmed.2022.874114"},{"key":"ref_4","first-page":"275","article-title":"Mechanisms of allergic rhinitis","volume":"6","author":"Park","year":"2023","journal-title":"Inflamm. Mech. Allerg. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13223-019-0375-9","article-title":"CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria","volume":"15","author":"Fein","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_6","first-page":"985","article-title":"Treatment of allergic rhinitis","volume":"92","author":"Sur","year":"2015","journal-title":"Am Fam Physician"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/dmd.107.019893","article-title":"Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration","volume":"37","author":"Zhao","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100795","DOI":"10.1016\/j.waojou.2023.100795","article-title":"Update meta-analysis on the efficacy and safety issues of fexofenadine","volume":"16","author":"Moreno","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_9","unstructured":"Department of Health and Human Services in US Food and Drug Administration (2022). Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules: Guidance for Industry."},{"key":"ref_10","first-page":"72","article-title":"Formulation and Evaluation of Fexofenadine HCL Oral Dispersable Tablets","volume":"3","author":"Kalla","year":"2020","journal-title":"Int. J. Res. Eng. Sci. Manag."},{"key":"ref_11","first-page":"279","article-title":"Polymorphism in fexofenadine hydrochloride","volume":"5","author":"Kulshrestha","year":"2013","journal-title":"Der Pharma Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1021\/acs.cgd.5b00317","article-title":"Separation of Active Pharmaceutical Ingredients (APIs) from excipients in pharmaceutical formulations","volume":"15","author":"Atwood","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, S., Wu, H., Zhao, Y., Zhang, R., Wang, Z., and Han, J. (2021). Solid form and phase transformation properties of fexofenadine hydrochloride during wet granulation process. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060802"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bhalani, D.V., Nutan, B., Kumar, A., and Chandel, A.K.S. (2022). Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092055"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1021\/acs.molpharmaceut.4c00234","article-title":"Influence of Solvent Selection on the Crystallizability and Polymorphic Selectivity Associated with the Formation of the \u201cDisappeared\u201d Form I Polymorph of Ritonavir","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcis.2004.05.015","article-title":"Solvent-based nanocomposite coatings: I. Dispersion of organophilic montmorillonite in organic solvents","volume":"278","author":"Duchet","year":"2004","journal-title":"J. Colloid Interface Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s13346-015-0256-9","article-title":"Amorphous solid dispersion technique for improved drug delivery: Basics to clinical applications","volume":"5","author":"Mishra","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_18","first-page":"100035","article-title":"Amorphous solid dispersion formation via solvent granulation\u2014A case study with ritonavir and lopinavir","volume":"1","author":"Trasi","year":"2019","journal-title":"Int. J. Pharm. X"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2022.01.036","article-title":"Nanoporous materials for pesticide formulation and delivery in the agricultural sector","volume":"343","author":"Singh","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39490","DOI":"10.1039\/C7RA06829H","article-title":"Design and pharmaceutical applications of porous particles","volume":"7","author":"Zhou","year":"2017","journal-title":"RSC Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejpb.2023.05.019","article-title":"The processes behind drug loading and release in porous drug delivery systems","volume":"189","author":"Farzan","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_22","unstructured":"U.S. Pharmacopeial Convention (2019). United States Pharmacopeia 42, National Formulary 37, U.S. Pharmacopeial Convention. Fexofenadine hydrochloride tablets."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0032-5910(02)00023-2","article-title":"Scale-up of mixer granulators for effective liquid distribution","volume":"124","author":"Litster","year":"2002","journal-title":"Powder Technol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/jps.24504","article-title":"Evaluating scale-up rules of a high-shear wet granulation process","volume":"104","author":"Tao","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1205\/cherd06205","article-title":"Effect of drug active substance particles on wet granulation process","volume":"85","author":"Belohlav","year":"2007","journal-title":"Chem. Eng. Res. Des."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15171\/bi.2015.04","article-title":"Granulation techniques and technologies: Recent progresses","volume":"5","author":"Shanmugam","year":"2015","journal-title":"BioImpacts"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1039\/C1JM13225C","article-title":"Role of pH and temperature on silica network formation and calcium incorporation into sol\u2013gel derived bioactive glasses","volume":"22","author":"Valliant","year":"2012","journal-title":"J. Mater. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpharm.2008.05.004","article-title":"Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats","volume":"361","author":"Ujie","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/cts.12400","article-title":"The pharmacokinetic exposure to fexofenadine is volume-dependently reduced in healthy subjects following oral admin-istration with apple juice","volume":"9","author":"Luo","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1208\/s12248-015-9753-5","article-title":"A bioequivalence approach for generic narrow therapeutic index drugs: Evaluation of the reference-scaled approach and variability comparison criterion","volume":"17","author":"Jiang","year":"2015","journal-title":"AAPS J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1871-5125(09)34004-2","article-title":"Fexofenadine hydrochloride","volume":"Volume 34","author":"Kumar","year":"2009","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:48:30Z","timestamp":1760032110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmaceutics17060756"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17060756","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}